Literature DB >> 2643736

Separation of urinary metabolites of radiolabelled estrogens in man by HPLC.

P E Lønning1, P Skulstad, A Sunde, T Thorsen.   

Abstract

A method to separate radiolabelled urinary estrogens by high performance liquid chromatography (HPLC) is described. Estrogen glucuronides were isolated from the urine of women receiving bolus injections of [4-14C]estrone or [4-14C]estradiol by adsorption on Sep-Pak C18 cartridges and subsequent DEAE Sephadex A25 column chromatography. Following enzyme hydrolysis, free estrogens were extracted and concentrated in methanol-water containing ascorbic acid. HPLC was performed either by C18 reversed phase chromatography using different concentrations of acetonitrile with or without tetrahydrofurane in phosphate buffer or methanol-water as mobile phases, or on a Diol column using chloroform-isooctane-n-hexane or isopropanol-isooctane-n-hexane as mobile phases. 3H-labelled estrogens were added as internal standards, and urinary [14C]estriol, [14C]estradiol and [14C]estrone concentrations could be measured with an interassay coefficient of variation less than 5%. Interassay coefficients of variation for [14C]2-hydroxyestriol, [14C]16 alpha-hydroxyestrone, [14C]2-hydroxyestradiol, [14C]2-hydroxyestrone and [14C]2-methoxyestrone were between 5 and 10%, while interassay coefficients of variation for [14C]4-hydroxyestrone was 14.6%. Recovery of the unstable catechol estrogen 2-hydroxyestrone was comparable to the recovery of the other estrogen metabolites, due to the addition of ascorbic acid throughout the different pre-chromatographic steps. Our method is suitable for the separation of the major labelled estrogen metabolites found in human urine following administration of radiolabelled estrone or estradiol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643736     DOI: 10.1016/0022-4731(89)90019-8

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  7 in total

1.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.

Authors:  F A MacNeill; S Jacobs; M Dowsett; P E Lonning; T J Powles
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Usefulness of early morning urine estrone-3-glucuronide assay in the monitoring ovarian secretory function in precocious puberty.

Authors:  F Bassi; O Bartolini; A S Neri; R G Gheri; A Magini; S Bucciantini; V Bruni
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

Review 4.  Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.

Authors:  Per Eystein Lønning; Hans Petter Eikesdal
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 5.  The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.

Authors:  P E Lønning
Journal:  Ann Oncol       Date:  2010-07-08       Impact factor: 32.976

6.  Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2008-12-18       Impact factor: 6.466

7.  The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.

Authors:  P E Lønning; S Jacobs; A Jones; B Haynes; T Powles; M Dowsett
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.